Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: VRTX

Vertex Pharmaceuticals Incorporated

Healthcare | Biotechnology
$528.04 +97.75 (+22.72%) as of 2026-07-14 20:06 UTC
Volume1.84M
EPS (TTM)$15.32

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a biotechnology company trading at $528.04 (+22.7% today) — 34.5× trailing earnings. Figures from SEC EDGAR and market feeds; updated 2026-07-14 20:06 UTC.

52-Week Range
Low $362.50High $529.08

What Vertex Pharmaceuticals Incorporated does

Vertex Pharmaceuticals is a global biotechnology company that develops medicines for serious diseases, particularly in specialty markets. The company has approved medicines for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain, and is advancing multiple mid- and late-stage clinical programs across additional serious diseases including kidney diseases, neuropathic pain, type 1 diabetes, and myotonic dystrophy type 1.

Summarized from Vertex Pharmaceuticals Incorporated’s SEC filings · Read the filing ↗

Key facts
Quote
Price$528.04
Change (1D)+97.75 (+22.72%)
Volume1.84M shares
52-week range$362.50 – $529.08
Valuation
P/E (TTM)34.47×
EPS (TTM)$15.32
Return on equity21.18%
Returns
52-week return+45.7%
Revenue, margins & earnings
FY2021 Net income: $2.34BFY2021 Taxes & interest: $440MFY2021 Operating costs: $4.79B$7.57BFY2021FY2022 Net income: $3.32BFY2022 Taxes & interest: $985MFY2022 Operating costs: $4.62B$8.93BFY2022FY2023 Net income: $3.62BFY2023 Taxes & interest: $212MFY2023 Operating costs: $6.04B$9.87BFY2023FY2024: net loss $536M on revenue $11.0B$11.0BFY2024FY2025 Net income: $3.95BFY2025 Taxes & interest: $220MFY2025 Operating costs: $7.83B$12.0BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-07
  • 2026-07-07McKechnie DuncanEVP, Chief Commercial OfficerSELL-1,541$799.8K
  • 2026-07-07Tatsis OuraniaEVP, Chief Reg. & Quality Off.SELL-1,500$787.5K
  • 2026-07-06Liu JoyEVP and Chief Legal OfficerSELL-828$416.2K
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • Capital World Investors25,368,124$11.33B-0.6%
  • VANGUARD GROUP INC24,105,529$10.93B-0.5%
  • BlackRock, Inc.23,191,085$10.36B-2.4%
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does Vertex Pharmaceuticals Incorporated do?

Vertex Pharmaceuticals is a global biotechnology company that develops medicines for serious diseases, particularly in specialty markets.

What is VRTX's valuation?

VRTX trades at $528.04, 34.47× trailing earnings, as of 2026-07-14.

When did VRTX last file with the SEC?

Vertex Pharmaceuticals Incorporated's most recent SEC filing on record is a 8-K filed 2026-07-07. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-14 20:06 UTC. This page is also available as JSON at /api/data?ticker=VRTX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for VRTX and 3,500+ tickers.

Create a free account — keep VRTX
For your agent
GET /api/data?ticker=VRTX

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt